buthionine sulfoximine has been researched along with Inclusion Body Myopathy, Sporadic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Akiyama, Y; Aoki, M; Hagiwara, Y; Hayashi, H; Hayashi, KI; Ichijo, M; Itoi, E; Izumi, R; Kanzaki, M; Kikuchi, K; Kodama, EN; Koide, M; Kure, S; Matsuhashi, T; Mishima, E; Ogata, Y; Oikawa, Y; Suzuki, C; Suzuki, N; Suzuki, T; Toyohara, T; Watanabe, S | 1 |
1 other study(ies) available for buthionine sulfoximine and Inclusion Body Myopathy, Sporadic
| Article | Year |
|---|---|
Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Buthionine Sulfoximine; Cell Survival; Cells, Cultured; DNA, Mitochondrial; Drug Evaluation, Preclinical; Dynamins; Female; Fibroblast Growth Factors; Fibroblasts; Growth Differentiation Factor 15; GTP Phosphohydrolases; Humans; Indoleacetic Acids; Male; Middle Aged; Mitochondria, Muscle; Myoblasts; Myositis, Inclusion Body; Oxygen Consumption; Phenylbutyrates; Reactive Oxygen Species; Retrospective Studies | 2020 |